Drug Trial Radar · NCT02100813
Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis
Last checked: Nov 20, 2026Latest source record: Mar 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
220
Actual
Start
May 2014
Primary completion
Mar 2015
Study completion Mar 2015
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Apr 1, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To identify the Maximum Tolerated Dose levels of LEO 43204 after once daily treatment for two consecutive days and to evaluate efficacy of LEO 43204 in two doses after once daily treatment for two consecutive days compared to vehicle
Conditions
- Actinic Keratosis
Interventions
LEO 43204Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants Experiencing a Dose-limiting Toxicity (DLT)Time frame: From Day 1 up to and including Day 8
- Part 2: Percent Reduction From Baseline in Actinic Keratosis (AK) Lesion CountTime frame: From baseline to Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gwinnett Clinical Research Center, Inc.
Snellville, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.